Etkin Amit 4
4 · Alto Neuroscience, Inc. · Filed Feb 7, 2024
Insider Transaction Report
Form 4
Etkin Amit
DirectorPRESIDENT AND CEO
Transactions
- Conversion
Common Stock
2024-02-06+11,777→ 1,202,340 total - Purchase
Common Stock
2024-02-06$16.00/sh+3,125$50,000→ 1,205,465 total - Conversion
Series B Preferred Stock
2024-02-06−25,000→ 0 total→ Common Stock (11,777 underlying)
Footnotes (1)
- [F1]Each share of Series B Preferred Stock was convertible at any time, at the holder's election, and automatically converted into shares of Common Stock immediately prior to the closing of the Issuer's initial public offering on a 2.1226069 for 1 basis and had no expiration date.